Data / Form D filings / Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.: Form D filings
Endeavor Biomedicines, Inc., a biotechnology company in San Diego, CA, filed 2 Form D notices with the SEC between 2022 and 2024. The latest, on May 3, 2024, reports $132.6 million sold of a $132.6 million offering to 32 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 12707 High Bluff Drive, Suite 300, San Diego, CA, 92130
- Phone
- (858) 537-1700
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1909364
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 3, 2024 | New notice | $132,583,908 | $132,583,908 | 32 | Apr 22, 2024 | sec.gov | |
| Feb 7, 2022 | New notice | $100,999,983 | $89,119,331 | $11,880,652 | 16 | Jan 21, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Patrick G. Enright | Director | |
| Bernard Davitian | Director | |
| John Hood | Executive Officer, Director | |
| Vishaal Turakhia | Executive Officer | |
| Chris Krueger | Executive Officer | |
| Enoch Kariuki | Executive Officer | |
| Karan Cheong Takhar | Director | |
| Miguel de los Rios | Executive Officer | |
| Monal Cheong Mehta | Director | |
| Wing Cheong Lam | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Apr 29, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Endeavor Biomedicines, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.